Union européenne - français - EMA (European Medicines Agency)

samsung bioepis nl b.v. - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; myopia, degenerative - ophtalmologiques - byooviz is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).

Union européenne - français - EMA (European Medicines Agency)

stada arzneimittel ag - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - ophtalmologiques - ximluci is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).

Union européenne - français - EMA (European Medicines Agency)

midas pharma gmbh - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - ophtalmologiques - ranivisio is indicated in adults for:• the treatment of neovascular (wet) age-related macular degeneration (amd)• the treatment of visual impairment due to diabetic macular oedema (dme)• the treatment of proliferative diabetic retinopathy (pdr)• the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)• the treatment of visual impairment due to choroidal neovascularisation (cnv).

Union européenne - français - EMA (European Medicines Agency)

novartis europharm limited - ranibizumab - wet macular degeneration; macular edema; diabetes complications; myopia, degenerative; choroidal neovascularization - ophtalmologiques - lucentis est indiqué chez l'adulte pour:le traitement de la forme néovasculaire (humide) liée à l'âge dégénérescence maculaire (dmla)le traitement de la déficience visuelle due à choroïdienne néovascularisation choroïdienne (nvc)le traitement de la déficience visuelle due à un œdème maculaire diabétique (dme)le traitement de la déficience visuelle due à un œdème maculaire secondaire à une occlusion veineuse rétinienne (direction de la rvo ou centrale rvo).

Canada - français - Health Canada

samsung bioepis co., ltd - ranibizumab - solution - 10mg - ranibizumab 10mg

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

samsung bioepis ch gmbh - ranibizumabum - solution injectable en flacon - ranibizumabum 10 mg, trehalosum dihydricum, histidini hydrochloridum monohydricum, histidinum, polysorbatum 20, aqua ad iniectabile q.s. ad solutionem pro 1 ml. - behandlung der exsudativen (feuchten) altersbezogenen makuladegeneration (feuchte amd), eines visusverlustes durch ein diabetisches makulaödem (dme),; eines visusverlustes durch ein makulaödem infolge eines retinalen venenverschlusses (retinaler venenastverschluss brvo und retinaler zentralvenenverschluss crvo), einer aktiven, den visus beeinträchtigenden choroidalen neovaskularisation (cnv), eines visusverlustes durch choroidale neovaskularisation (cnv) infolge einer pathologischen myopie (pm). - biotechnologika

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

novartis pharma schweiz ag - ranibizumabum - injektionslösung zur intravitrealen anwendung in durchstechflasche - ranibizumabum 10 mg, trehalosum dihydricum, histidini hydrochloridum monohydricum, histidinum, polysorbatum 20, aqua ad iniectabile q.s. ad solutionem pro 1 ml. - exsudative altersbezogene makuladegeneration, visusverlust duch diabetisches makulaödem, durch makulaödem infolge eines retinalen venenverschlusses und durch choroidale neovaskularisation infolge pathologischer myopie, aktive, den visus beeinträchtigende choroidale neovaskularisation, mässig schwere bis schwere npdr bzw pdr, frühgeborenen-retinopathie - biotechnologika

Canada - français - Health Canada

teva canada limited - ranibizumab - solution - 10mg - ranibizumab 10mg

Canada - français - Health Canada

novartis pharmaceuticals canada inc - ranibizumab - solution - 10mg - ranibizumab 10mg - eent drugs, miscellaneous

Canada - français - Health Canada

novartis pharmaceuticals canada inc - ranibizumab - solution - 10mg - ranibizumab 10mg - eent drugs, miscellaneous